Comparison of Emergence Agitation Between Remimazolam With Flumazenil and Propofol-based Total Intravenous Anesthesia in Patients Undergoing Nasal Surgery

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age19+
SponsorSeoul National University Hospital

About this trial

Participants will be randomly assigned to receive general anesthesia with either remimazolaml-based total intravenous anesthesia reversed with flumazenil or propofol-based total intravenous anesthesia. The primary outcome is the incidence of emergence agitation evaluated at the time of awakening after surgery. Additional outcomes include time to extubation, hemodynamic stability, airway complications such as coughing or laryngospasm, and postoperative recovery profiles including pain, nausea, vomiting, and sedation in the post-anesthesia care unit. This study aims to determine whether remimazolam with flumazenil provides smoother emergence compared with propofol in patients undergoing nasal surgery.

Eligibility criteria

Qualifiers

None

Disqualifiers

Declines or is unable to provide informed consent

Body mass index (BMI) ≥ 30 kg/m²

Pre-existing neurological or cognitive impairment

Known contraindication or allergy to remimazolam, propofol, or flumazenil

Trial design

Treatments tested in this trial

  • Remimazolam with Flumazenil
  • Propofol

Treatment groups

204 Participants
are divided into 2 treatment groups

Locations

This trial has no locations